Raymond James Raises Heska (NASDAQ:HSKA) Price Target to $145.00

Heska (NASDAQ:HSKA) had its target price upped by Raymond James from $140.00 to $145.00 in a report released on Thursday morning, AR Network reports. The brokerage currently has an outperform rating on the medical research company’s stock.

HSKA has been the subject of a number of other research reports. Piper Sandler raised Heska from a neutral rating to an overweight rating and increased their price objective for the company from $87.00 to $110.00 in a research note on Wednesday, August 5th. TheStreet raised Heska from a d+ rating to a c- rating in a research note on Tuesday, October 27th. Zacks Investment Research lowered Heska from a hold rating to a sell rating in a research note on Friday, October 23rd. BidaskClub raised Heska from a hold rating to a buy rating in a research note on Thursday, October 22nd. Finally, Alliance Global Partners raised their price target on Heska from $116.50 to $163.50 and gave the stock a buy rating in a research note on Wednesday, November 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $111.70.

NASDAQ:HSKA opened at $126.95 on Thursday. The firm has a market cap of $1.20 billion, a PE ratio of -57.18 and a beta of 1.70. Heska has a fifty-two week low of $50.00 and a fifty-two week high of $140.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.58 and a current ratio of 4.82. The business has a 50 day moving average price of $113.98 and a 200-day moving average price of $98.32.

Heska (NASDAQ:HSKA) last released its quarterly earnings data on Thursday, November 5th. The medical research company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.37). Heska had a negative net margin of 9.57% and a negative return on equity of 1.57%. Research analysts predict that Heska will post -0.68 EPS for the current year.

In other Heska news, Director Bonnie J. Trowbridge sold 4,917 shares of the stock in a transaction on Monday, November 9th. The stock was sold at an average price of $125.47, for a total value of $616,935.99. Following the completion of the transaction, the director now owns 5,435 shares in the company, valued at $681,929.45. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Nancy Wisnewski sold 1,500 shares of the stock in a transaction on Wednesday, November 18th. The stock was sold at an average price of $127.50, for a total value of $191,250.00. In the last quarter, insiders sold 24,017 shares of company stock valued at $2,738,378. 11.70% of the stock is owned by corporate insiders.

Several large investors have recently modified their holdings of the company. BlackRock Inc. increased its position in shares of Heska by 2.8% during the 3rd quarter. BlackRock Inc. now owns 1,298,015 shares of the medical research company’s stock valued at $128,232,000 after purchasing an additional 35,111 shares during the last quarter. Nine Ten Capital Management LLC increased its position in shares of Heska by 2.0% during the 3rd quarter. Nine Ten Capital Management LLC now owns 784,217 shares of the medical research company’s stock valued at $77,473,000 after purchasing an additional 15,096 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Heska by 16.8% during the 2nd quarter. Vanguard Group Inc. now owns 554,022 shares of the medical research company’s stock valued at $51,618,000 after purchasing an additional 79,600 shares during the last quarter. FMR LLC increased its position in shares of Heska by 2.0% during the 1st quarter. FMR LLC now owns 453,664 shares of the medical research company’s stock valued at $38,616,000 after purchasing an additional 8,870 shares during the last quarter. Finally, Standard Life Aberdeen plc increased its position in shares of Heska by 5.7% during the 3rd quarter. Standard Life Aberdeen plc now owns 333,345 shares of the medical research company’s stock valued at $32,932,000 after purchasing an additional 18,050 shares during the last quarter. Hedge funds and other institutional investors own 96.19% of the company’s stock.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

Read More: Are we seeing the beginning of a new bubble?

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.